Publikationen in Zusammenarbeit mit Forschern von Instituto Cajal (4)

2017

  1. The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease

    Journal of Psychiatry and Neuroscience, Vol. 42, Núm. 1, pp. 59-69

2016

  1. ASS234, as a new multi-target directed propargylamine for Alzheimer's disease therapy

    Frontiers in Neuroscience, Vol. 10, Núm. JUN

2014

  1. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 80, pp. 543-561

1999

  1. Stimulation of μ- and δ-opioid receptors enhances phosphoinositide metabolism in mouse spinal cord: Evidence for subtypes of δ-receptors

    European Journal of Neuroscience, Vol. 11, Núm. 6, pp. 2059-2064